HRT for estrogen deficiency symptoms in postmenopausal or ovariectomized women. Vasomotor (hot flashes, night sweats), genitourinary trophic (vulvovag atrophy, dyspareunia, urinary incontinence), & psychological (sleep disorders, asthenia) disorders. Prevention of osteoporosis in postmenopausal women at high risk of fracture who are intolerant of, or contraindicated to, drugs approved for osteoporosis prevention.
Postmenopausal symptoms Min effective dose: 1.25 g daily (equiv to 0.75 mg of estradiol) for 21-28 days/mth. Ave dose: 2.5 g daily. Prevention of osteoporosis Min effective dose: 2.5 g once daily.
Hypersensitivity. Known or suspected breast cancer; estrogen-dependent malignancies (eg, endometrial cancer). History of breast cancer. Vag bleeding of unknown etiology. Untreated endometrial hyperplasia. Previous or ongoing idiopathic VTE (DVT, pulmonary embolism). Known thrombophilic abnormalities (eg, protein C, protein S or antithrombin deficiency). Recent or ongoing arterial thromboembolic disease (eg, angina, MI). Porphyria. Acute liver disease or history of liver disease, as long as LFTs remain abnormal. Porphyria. Known or suspected pregnancy.
Discontinue use if breast tension, abdomen swelling, anxiety, irritability occurs. Not to be applied over breast or mucous membranes. Overwt, severe diabetes, high BP, endometriosis, kidney failure or hepatic disorders, epilepsy, asthma, lupus, pituitary tumour, porphyria, otospongiosis. History of CVA (haemorrhage or blood clot); family medical history of breast cancer. Bedridden patient. Scheduled surgery. Periodic medical exam for breast nodule or cyst prior to, or during treatment. Kidney failure or hepatic disorders. Itching during previous pregnancy. Pregnancy & lactation.
Sign Out
